1,721,034 research outputs found
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Full text linkWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
Human amnion-derived cells : prospects for the treatment of lung diseases
No full textLung diseases represent a significant burden of morbidity and mortality worldwide. Current therapies have not proven adequate in the long term and are often associated with significant side effects. There has been recent interest in the regenerative/reparative potential of cell-based therapies, including cells derived from the placental tissues. Amnion-derived cells are fetal-derived and characterized by expression profile and differentiative capacity of pluripotent cells. Moreover, because placenta is discarded after delivery, they represent an ethical source for the purposes of regenerative medicine. Amnion-derived cells are endowed with immunomodulatory, anti-inflammatory, anti-scarring and antibacterial properties, which may explain many of the beneficial effects observed with administration of the cells in animal models for a large number of inflammatory diseases. Both human amniotic epithelial cells (hAEC) and mesenchymal stromal cells (hAMSC) have been shown to acquire in vitro and in vivo some characteristics of epithelial cells, i.e. CFTR (cystic fibrosis transmembrane conductance regulator) and surfactant proteins. Administration of hAEC or hAMSC in vivo in the bleomycin-induced lung injury model has proven their therapeutic effects in term of reduction of pulmonary fibrosis and inflammation, as well as recovery of lung mechanical function. Many biological and clinical information have to be gathered before proposing amnion-derived cells in the clinic for the treatment of acute and chronic lung diseases
koamabayili/VECTRON-author-checklist: VECTRON author checklist
No full textWe have done our best to complete the author checklist relating to the use of animals in the hut study. Note that the objective for the hut study was to evaluate the IRS treatment applications for residual efficacy against Anopheles mosquitoes, including the local An. coluzzii mosquito population. Cows were only used to attract mosquitoes into the huts and no tests were carried out directly on the cows. The author checklist is intended for use with studies where experiments are carried out on animals, which is why we have had such difficulty in completing this for the hut study, as many of the questions do not relate to how the cows were used
A ciascuno il suo test : un progetto per ottimizzare l'utilizzo dell'analisi genetica per Fibrosi Cistica
No full textLa fibrosi cistica è caratterizzata da estrema eterogeneità genetica: sono più di mille le mutazioni ad oggi note. Vi sono fondamentalmente due tipologie di analisi genetica. La prima prevede la ricerca diretta di un numero variabile di mutazioni specifiche, le cui conseguenze cliniche sono note (I livello). La seconda utilizza sistemi di screening del gene, con sensibilità molto elevata, ma può individuare alterazioni nel gene dal significato poco chiaro, od anche ignoto, con conseguenti problemi di interpretazione del significato clinico del risultato (II livello). Attualmente sono disponibili kit commerciali di I livello per la ricerca di un numero limitato di mutazioni.
Le categorie di candidati all’analisi genetica si caratterizzano per rischi di eterozigosi a priori diversi. Per alcune è ragionevole ipotizzare che un test genetico di I livello, mutazione-specifico, sia sufficiente a ridurre apprezzabilmente il rischio di presenza di mutazioni. Per altre, in particolare quando si presenti un rischio di coppia non trascurabile in relazione a positività in uno dei due, o quando il rischio a priori sia alto, potrebbe essere indicato approfondire con sistemi di screening rapido del gene.
Di fatto, negli ultimi anni si è avuta un’escalation dell’offerta e della richiesta di analisi avanzate. Il desiderio di ottenere comunque la massima sensibilità di test disponibile sta rendendo sempre più diffuso l’utilizzo di analisi di II livello, complesse e non prive di effetti collaterali. I laboratori di genetica molecolare, in assenza di chiare linee guida di riferimento, non hanno ancora adottato strategie comuni nella tipologia d’intervento.
Obiettivi della Commissione sono: 1. Delineare per categorie di utenti e per situazioni l’indicazione al tipo di test genetico per fibrosi cistica. 2. Creare un documento di riferimento per le indicazioni all’uso delle varie tipologie di analisi genetica per fibrosi cistica
- …
